As governments and insurers strain to contain drug budgets, the companies that copy expensive originator therapies at lower cost occupy an unusual position: growth and affordability pull in the same direction. Sandoz Group, spun out of Novartis in October 2023, is the largest player of its kind by volume, spanning both conventional generics and the more technically demanding field of biosimilars.
The Quick Version
- Sandoz's primary listing is on the SIX Swiss Exchange as SDZ; 0SAN is a London trading line quoted in Swiss francs, not a separate primary listing.
- FY2025 net sales were USD 11.086 billion, up 7% in dollars and 5% at constant currency, with biosimilars growing 13% at constant currency to USD 3.292 billion.
- Management reports a biosimilar pipeline of 27 molecules targeting originator products with roughly USD 200 billion of sales across 2026-2035.
- Recent launches include denosumab (Wyost/Jubbonti), ustekinumab (Pyzchiva), natalizumab (Tyruko) and aflibercept (Afqlir in Europe); a US aflibercept launch is set for Q4 2026 after a Regeneron settlement.
- Generics pricing pressure, patent litigation, manufacturing execution and currency remain material uncertainties.
What Sandoz Actually Does
Sandoz's business divides into two segments. Generics, the larger segment, supplies chemically synthesised copies of small-molecule drugs once patents lapse. Biosimilars, smaller but faster-growing, produce close approximations of complex biologic medicines grown in living cells, requiring dedicated manufacturing and clinical comparability studies. Sandoz began trading independently on the SIX Swiss Exchange on 4 October 2023 under SDZ; the London line 0SAN is a secondary Swiss-franc trading line, not a sterling-quoted depositary receipt.
The 27-Molecule Biosimilar Pipeline
Sandoz's spring 2026 investor materials described a pipeline aimed at originator products with cumulative sales of roughly USD 200 billion across the US and Europe over 2026-2035. Developing, manufacturing and defending biosimilars through litigation and regulatory review is a considerably higher bar than conventional generics — which in turn helps limit competition, distinguishing the biosimilar opportunity from the more commoditised generics market.
Recent Launches
Tyruko (natalizumab) is the first and only biosimilar approved for relapsing multiple sclerosis in both the US and Europe, FDA-approved in 2023 before its US commercial launch in late 2025. Wyost and Jubbonti (denosumab) were the first denosumab biosimilars to reach the US market (June 2025), with European launch in December 2025. Pyzchiva (ustekinumab) launched in the US in February 2025. Afqlir/Enzeevu (aflibercept) launched in Europe in November 2025; a September 2025 Regeneron patent settlement permits a US launch of Enzeevu in Q4 2026, or earlier in certain circumstances.
The Numbers
For FY2025, net sales were USD 11.086 billion, up 7% reported (5% constant currency). Biosimilars rose 13% at constant currency to USD 3.292 billion — roughly 30% of group revenue. Generics grew 2% at constant currency to USD 7.794 billion, reflecting characteristic pricing pressure. Core EBITDA margin was 21.7%, up from 20.1%, and core net income was USD 1.589 billion (reported net income USD 914 million). Free cash flow was USD 874 million; net debt stood at USD 3.563 billion. The board proposed a dividend of CHF 0.80 per share.
For 2026, Sandoz guided to mid-to-high single-digit net sales growth at constant currency and approximately 100 basis points of core EBITDA margin expansion, assuming low-to-mid single-digit pricing declines and excluding any semaglutide contribution.
The Semaglutide Question
Management has flagged a potential future opportunity in generic and biosimilar versions of the GLP-1 molecule semaglutide, though it has deliberately excluded any such contribution from formal 2026 guidance — an appropriately cautious stance given the legal and regulatory complexity surrounding that class.
Competitive Position
Sandoz describes itself as the global leader in generics and biosimilars by volume. In biosimilars specifically it competes with Amgen, Samsung Bioepis, Celltrion, Biocon and Organon, among others. Competition is intense and molecule-specific — in aflibercept, for example, Amgen's biosimilar reached the US market first. Sandoz's differentiators include pipeline breadth, its manufacturing base, and first-mover status on selected molecules like natalizumab and denosumab — none of which is permanent.
Risks Worth Weighing
Generics pricing decline is persistent and can outpace volume gains. Biosimilar development is costly and uncertain, with clinical, regulatory and comparability hurdles that can delay or derail candidates. Patent litigation is recurring, as the Regeneron aflibercept dispute illustrates, and can shift launch timing materially. As a Swiss-domiciled group reporting in US dollars, Sandoz is exposed to currency movements affecting both reported results and the value of the London and Swiss quotes.
What to Watch Next
The planned US launch of the Enzeevu aflibercept biosimilar in Q4 2026 following the Regeneron settlement. Continued rollout of denosumab, ustekinumab and natalizumab biosimilars across markets. Regulatory progress on late-stage candidates such as the pembrolizumab programme. Periodic financial reporting testing whether 2026 growth and margin guidance is being met.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...